ACADIA
LIVE

Serial Number

99393417

Owner

Acadia Pharmaceuticals Inc.

Attorney

Carissa L. Weiss

Filing Date

Sep 15, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ACADIA Trademark

Serial Number: 99393417

ACADIA is a trademark filed by Acadia Pharmaceuticals Inc. on September 15, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 16 (Paper Goods), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Acadia Pharmaceuticals Inc.

12830 El Camino Real, Suite 400
San Diego, CA 92130

Entity Type: 03

Trademark Details

Filing Date

September 15, 2025

Registration Date

Not Registered

Goods & Services

Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions

Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support

Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals

Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders

Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals

Filing History

ASSIGNED TO EXAMINER
May 4, 2026 DOCK
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 8, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 8, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 9, 2026 GNRN
NON-FINAL ACTION E-MAILED
Feb 9, 2026 GNRT
NON-FINAL ACTION WRITTEN
Feb 9, 2026 CNRT
ASSIGNED TO EXAMINER
Feb 9, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 6, 2026 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 6, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Sep 15, 2025 MAFR
NEW APPLICATION ENTERED
Sep 15, 2025 NWAP